Read time: 1 minute
By: McKesson Health Systems Editorial Team
For patients facing rare diseases, high-cost medications known as orphan drugs can offer a chance at remission, recovery, or an improved quality of life. And for health systems that offer these advanced therapies, they can become a valuable differentiator in achieving more for their business of pharmacy.
Read McKesson’s recent article in collaboration with Becker’s Hospital Review, Investing in Impact: Orphan Drug Strategies to Maximize Business Performance and Improve Patient Outcomes, to discover why – despite certain obstacles – health systems are exploring the powerful potential of orphan drugs for their critical benefits.
Ready to learn how McKesson is working to help your health system achieve more? Contact our team now.
Share
Post
Post
Email